NCT00703742

A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Kunming Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is: 1. to find out the structural or functional effects of selective serotonin reuptake inhibitors (SSRI) in major depressive disorder (MDD); 2. find special abnormalities in depression secondary to other disease, e.g., autoimmune disease like systemic lupus erythematosus (SLE). 3. find the relationship between the efficacy of antidepressant and the change of neuroimaging in MDD 4. to find possible predispose to MDD 5. to explore the DNA methylation status in depression;

Detailed description

1. to explore the pathology of depression 2. to identify the difference between MDD and depression secondary to other disease ,especially autoimmune disease 3. to explore the effect of gene-environment interaction on the epigenetic regulation of the depression

Conditions

• Depression
• Depression Secondary to Other Disease

Interventions

Type	Name	Description
DRUG	Escitalopram	A,1: Escitalopram, oral, 20 mg/day, 8 weeks

Timeline

• Start date: 2008-06-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2008-06-23
• Last updated: 2019-09-17

Locations

1 site across 1 country: China